The development trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics

Background This paper aims to show the scientific research and technological development trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics. Methodology/Principal Findings Publications and patents related to antineoplastics targeting PD-1/PD-L1were searched and collected from the Web of Science (WoS) and the Derwent Innovation Index (DII) respectively. Totally, 11244 publications and 5501 patents were obtained. The publications were analyzed from the annual number, the top countries/regions and organizations to describe the scientific research trends in this field. The patents were analyzed from the annual number, the top priority countries and patent assignees to reveal the characteristics and status of technological development. As well as the identification of scientific research focus and technological development focus was based on the title and abstract of the publications and patents, using the freely available computer program VOSviewer for clustering and visualization analysis. The number of scientific publications and patent applications showed obvious increase of 29.84% and 33.46% in recent ten years (2009-2018), respectively. Results suggested that the most productive countries/regions publishing on antineoplastics targeting PD-1/PD-L1 were USA and China, and the top three productive organizations were all from USA, including Harvard University, VA Boston Healthcare System (VA BHS) and University Of California System. There were four scientific research focus: (1) immune escape mechanism, (2) biomarkers related to efficacy and prognosis, (3) immune-related adverse event, and (4) drug design and preparation, and five technological development focus: (1) testing methods and apparatus, (2) indications related to carcinoma, (3) biomarkers related to diagnosis and prognosis, (4) small molecule inhibitors, and (5) indications other than carcinoma. Conclusions/Significance The results of this study presents an overview of the characteristics of research status and trends of antineoplastics targeting PD-1/PD-L1, which could help readers broaden innovative ideas and discover new technological opportunities, and also serve as important indicators for government policymaking.

• Publication year

  2020

• Venue

  bioRxiv

• Publication date

  2020-05-01

• Fields of study

  Biology, Medicine, Political Science

• Identifiers
  DOI 10.1101/2020.05.01.072041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.

  2020cited by this paper
• Transcriptome-Guided Drug Repositioning

  2019cited by this paper
• Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.

  2019cited by this paper
• Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1

  2019cited by this paper
• Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

  2019cited by this paper
• Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study

  2019cited by this paper
• Research and development of anti-Parkinson’s drugs: an analysis from the perspective of technology flows measured by patent citations

  2019cited by this paper
• The Basics of Cancer Immunotherapy

  2018cited by this paper
• Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy

  2018cited by this paper
• Global patent landscape of programmed cell death 1: implications of the rapid expansion

  2018cited by this paper
• Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

  2018cited by this paper
• Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

  2018cited by this paper
• Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis

  2018cited by this paper
• Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets

  2018cited by this paper
• Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

  2018cited by this paper
• Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

  2017cited by this paper
• Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

  2017cited by this paper
• Scientometric and patentometric analyses to determine the knowledge landscape in innovative technologies: The case of 3D bioprinting

  2017cited by this paper
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

  2017cited by this paper
• Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.

  2017cited by this paper
• Cancer immunotherapy: The dark side of PD-1 receptor inhibition

  2017cited by this paper
• Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

  2017cited by this paper
• Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• Bibliometric spectroscopy of Russia’s nanotechnology: 2000–2014

  2017cited by this paper
• Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

  2017cited by this paper
• An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations

  2016cited by this paper
• Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

  2016cited by this paper
• Nivolumab for recurrent squamous-cell carcinoma of the head and neck

  2016cited by this paper
• Neurosciences in Brazil: a bibliometric study of main characteristics, collaboration and citations

  2016cited by this paper
• Drug Repositioning through Systematic Mining of Gene Coexpression Networks in Cancer

  2016cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cited by this paper
• Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

  2016cited by this paper
• Abstract 2362: Optimizing prostate cancer immunotherapy by reducing vaccine induced PD-1 expression

  2016cited by this paper
• corrigenda to Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [Ann Oncol 26 (2015) 2375-2391, doi: 10.1093/annonc/mdv383]

  2016cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.

  2016cited by this paper
• Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Identification of the Key Fields and Their Key Technical Points of Oncology by Patent Analysis

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Analysis of the Czech and Hungarian physiology publications 1994–2011

  2015cited by this paper
• 2013: Signaling Breakthroughs of the Year

  2014cited by this paper
• Patents in nanotechnology: an analysis using macro-indicators and forecasting curves

  2014cited by this paper
• PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.

  2014cited by this paper
• Checkpoint blocking antibodies in cancer immunotherapy

  2014cited by this paper
• Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Breakthrough of the year 2013. Cancer immunotherapy.

  2013cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Cancer immunotherapy

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway

  2012cited by this paper
• Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

  2011cited by this paper
• Bibliometric mapping of computer and information ethics

  2011cited by this paper
• A unified approach to mapping and clustering of bibliometric networks

  2010cited by this paper
• Software survey: VOSviewer, a computer program for bibliometric mapping

  2009cited by this paper
• Core technologies and key industries in Taiwan from 1978 to 2002: A perspective from patent analysis

  2005cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper

• Identification of technology frontiers of artificial intelligence-assisted pathology based on patent citation network

  2022cites this paper